ANNE-LAURE AUTRET-CORNET

About ANNE-LAURE AUTRET-CORNET

Anne-Laure Autret-Cornet holds a central leadership position at OSE Immunotherapeutics, a publicly listed biotech company focused on immuno-oncology and immuno-inflammation. She has served as Chief Financial Officer since May 2016, having joined Effimune in October 2013 as Administrative and Financial Manager before helping steer the merger with OSE Pharma that led to the creation of OSE Immunotherapeutics. In parallel with her financial responsibilities, she also oversees Human Resources and coordinates administrative and legal operations, giving her a broad, cross-functional view of the company’s internal organization. She was also elected as director representing employee shareholders at the General Shareholders’ Meeting held on June 22, 2023. Anne-Laure Autret-Cornet graduated from ESSCA School of Management, specializing in Audit-Finance, and earned the HEC Paris “Corporate Finance” certificate in 2020. She built her expertise at Deloitte, where she spent nearly seven years developing strong capabilities in audit and finance before moving into the biotechnology sector. This background gave her a combination of financial discipline, internal control expertise and an understanding of the operational realities of innovative companies advancing clinical-stage assets. At OSE Immunotherapeutics, she has helped structure and professionalize the finance function in a context of scientific and industrial growth, while the company advanced a portfolio of first-in-class drug candidates. Her responsibilities have included supporting the company’s funding strategy, strengthening financial visibility and backing the administrative framework of a listed biotech. Her profile reflects a strategic governance role at the intersection of finance, corporate organization and employee representation.